« Return to News | Drug Sponsors

Pfizer to cut 220 jobs in Spain

Thursday, September 22, 2011 11:41 AM

Pfizer has unveiled plans to cut its workforce in Spain by 11%, or 220 staff, driven by the financial crisis in Europe and regulatory moves in the country to reduce its healthcare spend, according to PharmaTimes.

The business newspaper Expansion has reported that Pfizer will present an ERE (opening the process of redundancies) which will apply to its administrative and sales forces teams. However, employees at Pfizer’s production facilities in Madrid and Olot (Girona) will not be affected.

A Pfizer official was quoted by Expansion as saying that the reasons for the cut are the financial woes being suffered by Europe as well as increasing costs of the Spanish healthcare system. The company is also concerned about new legislation passed by the central government and autonomies to push more generic use, as well as changes to the reference pricing system.

The news from Spain comes a week after reports that Pfizer is cutting more than 500 jobs in Germany, again as a result of changes in pricing regulations.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.